Key facts
- Bayesian Health’s last known valuation is $131.2M (Oct 2024).
- It has raised $40.0M across 1 recorded rounds; the latest was Early Stage VC ($15.0M) in Jul 2021.
- Notable investors include Andreessen Horowitz, US National Science Foundation, Catalio Capital Management, Lifeforce Capital, Emerald Development Managers — 13 tracked in total.
- Status: Privately Held (backing).
Leadership
- Suchi SariaFounder & CEO
- Martin DoerflerChief Medical Officer
- Neri CohenHead of Clinical Enterprise
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Bayesian Health
Funding rounds
1 roundsAbout Bayesian Health
Developer of a real-time healthcare software designed to give healthcare teams real-time data for health systems. The company's software applies artificial intelligence and machine learning to multi-layered clinical data sets to offer real-time access to inferences that make care safer and more efficient, enabling healthcare providers to make patient-specific data-driven decisions in highly complex clinical areas.
- Industry
- Healthcare
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2016
- Employees
- 47
- Website
- bayesianhealth.com/
- Ownership
- Privately Held (backing)
Bayesian Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bayesian Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bayesian Health in its N-PORT filings yet. We sweep new filings monthly.